肺肉瘤样癌3例  

Pulmonary sarcomatoid carcinoma:report of three cases

作　　者：王志霞 王业明[1] 沈亚青 吴燕梅 王宁[1] 任晓霞 张晓雷 Wang Zhixia;Wang Yeming;Shen Yaqing;Wu Yanmei;Wang Ning;Ren Xiaoxia;Zhang Xiaolei(Department of Pulmonary and Critical Care Medicine,Center of Respiratory Medicine,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]中日友好医院呼吸与危重症医学科,国家呼吸医学中心,中国医学科学院呼吸疾病研究院,国家呼吸疾病临床研究中心,北京100029

出　　处：《中华结核和呼吸杂志》2024年第10期960-964,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：肺肉瘤样癌是一种临床罕见的非小细胞肺癌亚型, 侵袭性强, 治疗效果差, 生存期短, 预后差, 发病机制不明。本文报道3例肺肉瘤样癌分别有EGFR L858R、BRAF V600E、ALK靶向基因突变, 分析比较其临床特征并复习相关文献, 以期提高临床医师对该病的认识和诊治水平, 为后续肺肉瘤样癌驱动基因的筛查和分子靶向药物的开展提供依据。Pulmonary sarcomatoid carcinoma(PSC)is a rare disease with strong aggressiveness,low response rates to treatment,short survival span and poor prognosis,belonging to a group of non-small cell lung carcinomas(NSCLC)that remains incompletely understood.Here,we presented three PSC cases with epidermal growth factor receptor(EGFR)L858R,BRAF V600E and ALK mutations respectively,described their clinical characteristics and conducted a review of literature,in order to improve its therapeutic level,which also provided evidence-based medical evidence for driver gene screening and molecular targeted drug application in PSC patients.

关 键 词：肺肉瘤样癌 临床医师 非小细胞肺癌 分子靶向药物 预后差 驱动基因 BRAF 临床特征 

分 类 号：R734.2[医药卫生—肿瘤]